ENDPOINTS NEWS5h
Trump picks RFK Jr. for HHS; Ab­b­Vie's psych im­plo­sion; Mer­ck tries staving off Sum­mit; and more
AbbVie faced setbacks with emraclidine's dual pivotal trial failures in schizophrenia treatment, impacting their $8.7B ...
ENDPOINTS NEWS18h
Il­lu­mi­na seeks to dis­miss share­hold­er law­suit, de­nies se­cret $800M stake
Illumina has moved to dismiss a securities lawsuit against the company’s board members over their $8 billion Grail deal, ...
ENDPOINTS NEWS21h
Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy
Trump's HHS nominee Robert F. Kennedy Jr., an anti-vaccine advocate calling for stricter pharma oversight, contrasts with ...
ENDPOINTS NEWS22h
Eu­ro­pean drug reg­u­la­tors of­fer wave of pos­i­tive rec­om­men­da­tions fol­low­ing Leqem­bi re­ver­sal
EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...